1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Key Pharma News 20 OCTOBER 2014

Key Pharma News 20 OCTOBER 2014

  • October 2014
  • -
  • Espicom Business Intelligence
  • -
  • 40 pages

Industry Trend Analysis - Shire/AbbVie Combination Now Unlikely
Industry Trend Analysis - J&J Bolsters Immunotherapy Pipeline With Second Aduro Collaboration
Industry Brief - Eisai Names Partner For Pan Middle-East Distribution Of Fycompa
Industry Trend Analysis - M&A Activity Still Strong Despite Efforts To Prevent Tax Inversions
Industry Brief - Baxter To Form New Global Innovation/R&D Centre For Biopharmaceuticals Business
Industry Brief - Bayer Completes Acquisition Of Merck's Consumer Care Business; Collaboration Comes Into Effect
Industry Brief - Islet Sciences/BHV Pharma Plan Merger To Create Avogenx
Industry Brief - Prima BioMed To Acquire Immutep
Industry Trend Analysis - Salix/Cosmo Merger Thwarted By Tax Inversion Rules
Industry Brief - Shasun/Strides To Amalgamate
Industry Brief - Endo To Expand Pharmaceutical Business With Auxilium
Industry Brief - Meda Completes Rottapharm Acquisition
Industry Trend Analysis - J&J Results Reveal Immunology Drug Stelara's Stellar Potential
Industry Brief - Daiichi Sankyo Submits Tender Offer For Shares In Ambit Biosciences
Industry Trend Analysis - Genentech Faces Backlash Over Cancer Drug Distribution Changes
Industry Brief - Zogenix Submits sNDA For Modified Formulation Of Zohydro ER
Industry Trend Analysis - Harvoni Approval Timed Perfectly With FDA Increase In Market Exclusivity
Industry Trend Analysis - Rapidly Evolving HCV Market Sees Further Withdrawal
Industry Trend Analysis - Akynzeo To Compete With Merck's Emend In CINV Prevention
Industry Brief - BMS Resolves Efavirenz US Patent Litigation
Industry Trend Analysis - Teva Behind In Abuse-Deterrent Hydrocodone ER Race
Industry Brief - FDA Approves Velcade For Previously Untreated Patients With MCL
Industry Trend Analysis - UK's NICE Continues Rejection Trend With Obinutuzumab
Industry Trend Analysis - Paediatric Approval Could Push Stelara To Forefront
Industry Brief - Amgen Receives FDA Priority Review Designation For Blinatumumab In ALL
Industry Trend Analysis - Pfizer's Palbociclib On Route For 2015 Launch
Industry Trend Analysis - Race For First US IPF Treatment Is A Dead Heat
Industry Brief - Eisai's Lenvatinib Gains FDA Priority Review Designation For RAI-Refractory DTC
Industry Trend Analysis - Teva Follows De-Diversification Trend With Focus On CNS/Respiratory
Industry Trend Analysis - Immunotherapy-Targeted Research Data Highlighted At ESMO 2014
Industry Trend Analysis - Nanobiotix' NBTXR3 To Make The Unresectable Resectable
Industry Brief - Shantha's Rotavirus Vaccine Enters Phase III Trial In India
Industry Trend Analysis - Roche To Provide Competitor To GSK's Melanoma Combination
Industry Trend Analysis - Breakthrough Designation Signals More Positive Future For ARIAD
Industry Brief - Vosaroxin/Cytarabine Phase III Trial Fails To Meet Primary Endpoint
Industry Brief - AnGes Initiates Global Phase III Trials Of Collategene In Critical Limb Ischaemia
Industry Trend Analysis - Amgen's Biosimilar Programme Progresses
Industry Trend Analysis - New Wave Of ALK Inhibitors Set To Enter Market
Industry Trend Analysis - Personalised Therapy Becoming A Mainstay In Cancer Treatment

Table Of Contents

Key Pharma News 20 OCTOBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

  • $ 75000
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both ...

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.